Latest Memphasys (ASX:MEM) News

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.

Memphasys secures a follow-up order for its Felix™ sperm selection cartridges from a leading Japanese fertility clinic, marking growing adoption in one of the world’s largest IVF markets and signaling a strategic shift to direct sales.

Memphasys Limited has disclosed a $1.118 million liability linked to its FY24 R&D tax rebate following an ASX inquiry, while confirming compliance with continuous disclosure rules and ongoing engagement with the ATO for a private ruling.

Memphasys Limited has announced a pro-rata entitlement offer to raise approximately $1.12 million, issuing new shares at $0.003 each with free attaching options, aiming to fund the commercialisation of its Felix™ system and strengthen working capital.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.

Memphasys has upgraded its contract with ITL to A$390,000 and expanded its territory to include Turkey, marking its first contracted revenues in the EU ahead of expected CE Mark approval.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.